SureTrader Nadex Advertisement PGUS
Home > Boards > US Listed > Medical - Drugs >

AVEO Pharmaceuticals, Inc. (AVEO)

AVEO RSS Feed
Add AVEO Price Alert      Hide Sticky   Hide Intro
Moderator: mick
Search This Board: 
Last Post: 3/23/2017 10:38:04 PM - Followers: 82 - Board type: Free - Posts Today: 0

AVEO ONCOLOGY, Inc. (AVEO) 


Company website: 
http://www.aveooncology.com/

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company is focused on developing and commercializing its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for Renal Cell Carcinoma and other cancers. AVEO is leveraging multiple partnerships to develop and commercialize tivozanib in non-oncologic indications worldwide and oncology indications outside of North America, as well as to progress its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome).


   

Product pipeline candidates include tivozanib, ficlatuzumab, AV-203 and AV-380.
 
 

AV-380 (GDF-15 Program)

In August 2015, AVEO announced an exclusive, worldwide license agreement with Novartis for the development and commercialization of AVEO’s first-in-class, potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), AV-380, and related antibodies, including modified or derivative forms of any such antibody.

GDF15 is a pro-inflammatory cytokine whose elevated circulating levels have been correlated with cachexia in cachectic cancer patients and several animal models of cancer cachexia. Current evidence suggests that a pro- inflammatory state may be responsible for many of the symptoms associated with cachexia, a complex metabolic syndrome characterized by malnutrition and severe involuntary weight loss due to the loss of muscle and fat tissue, as well as the clinical manifestation of anemia, inflammation and suppression of immune functions.

Preclinical data show that inhibition of GDF15 results in a switch from catabolism to anabolism, suggesting that GDF15 inhibition with AV-380 may reverse the effects of cachexia.
Cachexia is a serious and common complication in patients with advanced cancer and other chronic diseases. It affects some five million individuals in the United States.

Tivozanib

Tivozanib, is a potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities.

AVEO remains encouraged by the clinical outcomes from its Phase 2 and Phase 3 studies in renal cell carcinoma and the efficacy and tolerability profile that tivozanib may offer to patients suffering from this challenging disease. In addition, promising biomarker results were observed in a Phase 2 study of tivozanib in colorectal cancer.

In August of 2014, AVEO regained all rights to tivozanib. In November 2014, AVEO entered into an option agreement with Ophthotech to investigate tivozanib for the potential treatment of non-oncologic diseases of the eye. In August 2015, AVEO entered into an exclusive license agreement with Pharmstandard OJSC for the development, manufacturing and commercialization of tivozanib in the territories of Russia, Ukraine and the Commonwealth of Independent States (CIS), for all indications excluding ocular conditions. The Company is actively pursuing partnerships in Europe to advance the development and commercialization of tivozanib in solid tumors.

AVEO is interested in collaborating with potential partners who share our vision for cancer drug development and positively impacting patients’ lives. Please contact AVEO [email protected] to discuss partnership opportunities with AVEO’s development pipeline.

Ficlatuzumab

Ficlatuzumab (formerly known as AV-299) is a potent hepatocyte growth factor (HGF) inhibitory antibody that binds to the HGF ligand with high affinity and specificity to inhibit HGF/c-Met biological activities.

AVEO and Biodesix, Inc. have a worldwide agreement to develop and commercialize ficlatuzumab, with VeriStrat®, a serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). Under the terms of the agreement, AVEO and Biodesix are conducting a proof-of-concept study of ficlatuzumab in combination with erlotinib in advanced NSCLC patients selected using BDX001, a serum protein test similar to the VeriStrat test.

An exploratory analysis from AVEO’s Phase 2 study in first-line NSCLC suggested that VeriStrat was prognostic for outcome in the epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI)-treated patients and predicted differential treatment benefit for the combination of ficlatuzumab plus TKI over TKI alone. The predictive effect was observed in both progression-free survival and overall survival endpoints
 

AV-203

AVEO scientists have demonstrated through the use of our Human Response Platform™ the importance of ErbB3 in promoting tumor growth. An increasing body of evidence also implicates the activation of ErbB3 in tumorigenesis and the development of resistance to anti-cancer agents. AV-203 is a clinical-stage ErbB3 (HER3) inhibitory antibody candidate designed to inhibit both ligand-dependent and ligand-independent ErbB3 signaling. ErbB3 is a receptor that is typically expressed in many human cancers, and AV-203 has demonstrated preclinical activity in a number of different tumor models including breast, head and neck, lung, ovarian and pancreatic cancers.

AVEO has successfully completed a Phase 1 safety study showing no dose limiting toxicities at maximum dose of 20mg/kg and CLIA (Clinical Laboratory Improvements Amendment) validation has been completed for a biomarker for potential patient selection.


 
www.aveopharma.com
Shares Outstanding   55,070,000
Institutional Ownership  31%
57 Employees
http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-irhome
 
  
One Broadway 14th Floor
Cambridge, MA 02142

Investor Relations
Phone: 617-588-1960
E-mail: [email protected]

 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AVEO
Current Price
Volume:
Bid Ask Day's Range
SureTrader
AVEO News: Current Report Filing (8-k) 03/22/2017 04:22:21 PM
AVEO News: Annual Report (10-k) 03/22/2017 04:20:41 PM
AVEO News: AVEO Reports Full Year 2016 Financial Results and Provides Business Update 03/22/2017 04:05:00 PM
AVEO News: AVEO Announces First Patient Dosed in Phase 1/2 TiNivo Trial of Tivozanib and Opdivo® (nivolumab) in Advanced RCC 03/22/2017 07:00:00 AM
AVEO News: Notification That Annual Report Will Be Submitted Late (nt 10-k) 03/17/2017 04:16:35 PM
PostSubject
#1839  Sticky Note $AVEO recent news/filings mick 11/17/15 10:42:39 AM
#2457   They need to borrow about 50 million so Apophis 03/23/17 10:38:03 PM
#2456   They have until 4/10 or so to have Full Contact Yoga 03/23/17 03:03:32 PM
#2455   cash burn may kill this before any drugs Apophis 03/23/17 02:20:26 PM
#2453   Pretty shitty Q. Bailey needs to be replaced, incompetent. Full Contact Yoga 03/23/17 09:17:16 AM
#2452   AVEO Reports Full Year 2016 Financial Results and ProfitScout 03/22/17 04:10:12 PM
#2451   AVEO News: AVEO Announces First Patient Dosed in mick 03/22/17 12:05:27 PM
#2450   Aveo Pharmaceuticals (AVEO) mick 03/22/17 12:05:19 PM
#2449   AVEO Announces First Patient Dosed in Phase 1/2 ProfitScout 03/22/17 09:25:27 AM
#2448   check their website, I do not think they Apophis 03/13/17 01:48:55 PM
#2447   Earnings coming this week. TDAmeritrade says March 13th, The2ndAmendment 03/11/17 06:06:11 PM
#2446   I'm gonna keep this stock for long. From The2ndAmendment 03/10/17 09:06:38 AM
#2445   nothing more than the news they released. Apophis 03/10/17 08:47:32 AM
#2444   I just purchased a couple shares today. Looks The2ndAmendment 03/08/17 06:06:24 PM
#2443   It would be nice to form a new Apophis 03/08/17 07:48:04 AM
#2442   I'm with you Selett. I was fortunate enough twistedfreak 03/07/17 04:56:39 PM
#2441   Looking pretty plausible Apophis. Great looking steady climb twistedfreak 03/07/17 04:54:27 PM
#2440   Very nice. Still can't believe how low this got Selett 03/07/17 02:22:31 PM
#2439   It would be nice to see $1.00 by Apophis 03/07/17 11:49:28 AM
#2438   Once this gets its first drug approval then Apophis 03/01/17 02:17:15 PM
#2437   AVEO is clearly on a new uptrend now. ProfitScout 03/01/17 10:23:01 AM
#2436   new buying should put this over $2.40 soon Apophis 03/01/17 10:12:50 AM
#2435   AVEO Announces TIVO-3 Passes The First Safety Monitoring ProfitScout 02/23/17 09:23:30 AM
#2434   this could all be pre merger action/buying. Apophis 02/15/17 07:03:23 PM
#2433   50 DMA (.623) last week, 100 DMA (.673) alexander77 02/15/17 04:12:15 PM
#2432   Nice volume and climb... Full Contact Yoga 02/15/17 10:43:38 AM
#2431   The price is holding up in premarket Apophis 02/15/17 09:24:20 AM
#2430   Today the 100DMA(0.678)has been succesfully broken in a alexander77 02/14/17 04:17:56 PM
#2429   I think they presented today, someone must have Selett 02/14/17 03:36:30 PM
#2428   Up 14%, some one is buying in big time Apophis 02/14/17 03:26:56 PM
#2427   Meaningful. Feb 8 twistedfreak 02/13/17 09:46:14 AM
#2426   just a start, several other things need to Apophis 02/12/17 10:36:35 AM
#2425   AVEO breached its' 50DMA in a bullish manner alexander77 02/11/17 04:05:12 PM
#2424   NICE A.H. PPS ACTION AVEO mick 02/11/17 02:28:46 PM
#2423   AVEO News: Statement of Changes in Beneficial Ownership mick 02/11/17 02:28:20 PM
#2422   Aveo Pharmaceuticals (AVEO) mick 02/11/17 02:28:12 PM
#2421   An insider just bought 210,000 shares :) Apophis 02/11/17 01:21:52 PM
#2420   AVEO Announces Clinical and Regulatory Updates for Tivozanib ProfitScout 02/09/17 04:21:59 PM
#2419   I agree. But more like 10dollars/share alexander77 02/07/17 11:27:04 AM
#2418   The next several months are do or die Apophis 02/07/17 08:38:33 AM
#2417   AVEO to Present at the 19th Annual BIO ProfitScout 02/06/17 08:23:43 AM
#2414   Not sure what you mean by timing. I Full Contact Yoga 01/20/17 07:50:36 AM
#2413   Welcome back FCY! I love your timing. twistedfreak 01/20/17 07:37:40 AM
#2412   Wow, Bailey truly sucks, facing delisting on multiple Full Contact Yoga 01/19/17 08:37:26 PM
#2411   Hope some good news comes in that lifts rivervalley 01/12/17 08:34:44 PM
#2410   It is time for a 10:1 reverse split Apophis 01/12/17 06:46:22 PM
#2409   The speech the new pres did today had rivervalley 01/11/17 01:19:45 PM
#2408   That would be great, but still at least Full Contact Yoga 01/06/17 11:21:22 AM
#2407   What about the EUSA milestone payment if the twistedfreak 01/06/17 10:39:20 AM
#2406   No milestone payment, slumming under $1 for quite Full Contact Yoga 01/06/17 10:14:28 AM
#2405   INSTITUTIONAL OWNERSHIP HAS SOME NEW POSITIONS, I AM Apophis 01/05/17 10:28:18 AM
PostSubject